ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026. The meeting covered the adoption of financial statements and director re-appointment.
Sudarshan Pharma stated its proposed 9.50% stake acquisition of Med Therapy Biotechnology Inc. remains under due diligence. Promoter acquisitions of 1.50% each are also pending.
Sudarshan Pharma Industries Ltd announced the release of a pledge of 20,00,000 equity shares held by its promoter, Mr. Hemal Mehta. This disclosure complies with SEBI regulations.
Sudarshan Pharma Industries will acquire a 9.50% stake in MedTherapy Biotechnology Inc. for cash. Its promoters will separately acquire an additional 3% combined stake.
Sudarshan Pharma Industries Ltd has filed its Annual Report for the Financial Year 2025-26 with the exchange, pursuant to SEBI Regulation 34.
Sudarshan Pharma Industries Ltd has issued the notice for its 18th Annual General Meeting, scheduled to be held on September 22, 2026, via video conferencing.
Promoters Hemal V Mehta and Sachin V Mehta have created a pledge on 13,200,000 equity shares of the company as security for a loan.
Sudarshan Pharma Industries Ltd allotted 48,11,730 equity shares upon conversion of FCCBs. The conversion value is approximately ₹14.25 Crore.
Sudarshan Pharma Industries reports on its specialty chemicals and pharmaceutical business, highlighting the turnaround of Ratna Lifescience and strategic vertical integration into API manufacturing and branded generics.
Sudarshan Pharma Industries Ltd will acquire 3,000 shares, representing a 30% stake, in Sudarshan Maven Pharma Private Limited. This strategic acquisition will make the entity a wholly-owned subsidiary.
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹174.4 Cr (+20.0% YoY) and net profit of ₹5.6 Cr (+40.0% YoY) for Q1 FY27.
Promoter Hemal Vasantrai Mehta released a pledge of 20,00,000 shares of Sudarshan Pharma Industries Limited. The shares were previously encumbered for personal loan reasons.
Sudarshan Pharma Industries Ltd has scheduled a board meeting for August 12, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
Sudarshan Pharma Industries Ltd submitted its quarterly shareholding pattern under Regulation 31. This periodic disclosure provides details on promoter and public equity ownership.